文献速递血栓与止血

艾美赛珠单抗预防治疗伴抑制物儿童血友病A的多中心3期研究

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
PubMed 文献 · Blood · 2019-01-01

HAVEN 2是一项多中心、开放标签3期研究,评估艾美赛珠单抗皮下预防治疗伴FVIII抑制物的<12岁血友病A患儿。与既往旁路制剂预防相比出血率降低99%。最常见不良事件为上呼吸道感染和注射部位反应,无血栓事件。

要点

  • 艾美赛珠单抗预防治疗可显著降低伴抑制物血友病A患儿的年化出血率。
  • A组每周方案年化出血率0.3,77%患儿无治疗出血事件。
  • 个体内比较显示较旁路制剂预防出血率降低99%,无血栓事件。

核心结论

  • 艾美赛珠单抗预防治疗对伴抑制物的儿童血友病A高度有效,且安全性可控。

研究设计与样本

  • 患儿既往接受按需或预防性旁路制剂治疗,后接受皮下艾美赛珠单抗:A组1.5 mg/kg每周(n=65)、B组3 mg/kg每2周(n=10)、C组6 mg/kg每4周(n=10)。
  • 评估药代动力学、安全性和疗效,包括来自非干预研究的15例患儿的个体内比较。

主要发现

  • A组年化治疗出血事件率(ABR)为0.3(95%CI 0.17-0.50),77%无治疗出血事件。
  • 15例既往接受旁路制剂预防的患儿个体内比较显示,艾美赛珠单抗预防使ABR降低99%(95%CI 97.4-99.4)。
  • B组和C组ABR分别为0.2(95%CI 0.03-1.72)和2.2(95%CI 0.69-6.81)。
  • 最常见不良事件为鼻咽炎和注射部位反应;无血栓事件发生。
  • 88例参与者中2例出现中和性抗药抗体,1例疗效丧失,另1例抗体自行消失且无突破性出血。

关键数值与推荐

  • A组(每周1.5 mg/kg)ABR 0.3(95%CI 0.17-0.50),77%无治疗出血事件。
  • B组(每2周3 mg/kg)ABR 0.2(95%CI 0.03-1.72);C组(每4周6 mg/kg)ABR 2.2(95%CI 0.69-6.81)。
  • 个体内比较ABR降低99%(95%CI 97.4-99.4)。
  • 88例中2例出现中和性抗药抗体,1例疗效丧失,1例抗体自行消失。

临床怎么用

  • 艾美赛珠单抗皮下预防治疗可作为伴抑制物儿童血友病A的有效选择,需监测抗药抗体及疗效。

局限性

  • B组和C组样本量较小(各10例),置信区间较宽。
  • 开放标签设计,疗效评估可能受主观因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emicizumab, a bispecific humanized monoclonal antibody, bridges activated factor IX (FIX) and FX to restore the function of missing activated FVIII in hemophilia A. Emicizumab prophylaxis in children with hemophilia A and FVIII inhibitors was investigated in a phase 3 trial (HAVEN 2). Participants, previously receiving episodic/prophylactic bypassing agents (BPAs), were treated with subcutaneous emicizumab: 1.5 mg/kg weekly (group A), 3 mg/kg every 2 weeks (group B), or 6 mg/kg every 4 weeks (group C). Pharmacokinetics, safety, and efficacy (including an intraindividual comparison of participants from a noninterventional study) were evaluated. Eighty-five participants aged <12 years were enrolled. In group A (n = 65), the annualized rate of treated bleeding events (ABRs) was 0.3 (95% confidence interval [CI], 0.17-0.50), and 77% had no treated bleeding events. Intraindividual comparison of 15 participants who previously took BPA prophylaxis showed that emicizumab prophylaxis reduced the ABR by 99% (95% CI, 97.4-99.4). In groups B (n = 10) and C (n = 10), ABRs were 0.2 (95% CI, 0.03-1.72) and 2.2 (95% CI, 0.69-6.81), respectively. The most frequent adverse events were nasopharyngitis and injection-site reactions; no thrombotic events occurred. Two of 88 participants developed antidrug antibodies (ADAs) with neutralizing potential, that is, associated with decreased emicizumab plasma concentrations: 1 experienced loss of efficacy, and, in the other, ADAs disappeared over time without intervention or breakthrough bleeding. All other participants achieved effective emicizumab plasma concentrations, regardless of the treatment regimen. Emicizumab prophylaxis has been shown to be a highly effective novel medication for children with hemophilia A and inhibitors. This trial was registered at www.clinicaltrials.gov as #NCT02795767.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019. PMID: 31697801. doi:10.1182/blood.2019001869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。